OBJECTIVES: Myxovirus resistance protein A (MxA) can be used as a marker of the bioactivity of interferon-beta (IFN-beta) therapy. Two to forty per cent of IFN-beta-treated multiple sclerosis (MS) patients develop IFN-beta-neutralizing antibodies (NAb) with subsequent attenuation of MxA protein induction. The aim of this study was to set up a simple MxA enzyme immunoassay (EIA) for the measurement of MxA protein and to evaluate the EIA test by comparing the results with flow cytometric analysis and the measurement of NAb. METHODS: total of 51 IFN-beta-treated relapsing-remitting MS (RRMS) patients were tested for MxA protein expression by using both MxA EIA assay and flow cytometric analysis. Thirteen patients were confirmed to be NAb-positive. RESULTS: The correlation between EIA and flow cytometric analysis was significant with a wider range of measured levels in the EIA. Patients with NAb had low MxA levels, but in some patients, remaining MxA induction could be detected despite NAb. CONCLUSIONS: The MxA EIA assay seems to be a practical method for large-scale analysis of the bioactivity of IFN-beta treatment.
OBJECTIVES: Myxovirus resistance protein A (MxA) can be used as a marker of the bioactivity of interferon-beta (IFN-beta) therapy. Two to forty per cent of IFN-beta-treated multiple sclerosis (MS) patients develop IFN-beta-neutralizing antibodies (NAb) with subsequent attenuation of MxA protein induction. The aim of this study was to set up a simple MxA enzyme immunoassay (EIA) for the measurement of MxA protein and to evaluate the EIA test by comparing the results with flow cytometric analysis and the measurement of NAb. METHODS: total of 51 IFN-beta-treated relapsing-remitting MS (RRMS) patients were tested for MxA protein expression by using both MxA EIA assay and flow cytometric analysis. Thirteen patients were confirmed to be NAb-positive. RESULTS: The correlation between EIA and flow cytometric analysis was significant with a wider range of measured levels in the EIA. Patients with NAb had low MxA levels, but in some patients, remaining MxA induction could be detected despite NAb. CONCLUSIONS: The MxA EIA assay seems to be a practical method for large-scale analysis of the bioactivity of IFN-beta treatment.
Authors: Erika Huijser; Jens Göpfert; Zana Brkic; Cornelia G van Helden-Meeuwsen; Sanne Jansen; Thomas Mandl; Peter Olsson; Benjamin Schrijver; Marco W J Schreurs; Paul L A van Daele; Willem A Dik; Marjan A Versnel Journal: Rheumatology (Oxford) Date: 2022-05-05 Impact factor: 7.046
Authors: Naomi I Maria; Zana Brkic; Matti Waris; Cornelia G van Helden-Meeuwsen; Kim Heezen; Joop P van de Merwe; Paul L van Daele; Virgil A S H Dalm; Hemmo A Drexhage; Marjan A Versnel Journal: Ann Rheum Dis Date: 2013-07-06 Impact factor: 19.103
Authors: Laura Toivonen; Linnea Schuez-Havupalo; Maris Rulli; Jorma Ilonen; Jukka Pelkonen; Krister Melen; Ilkka Julkunen; Ville Peltola; Matti Waris Journal: J Clin Virol Date: 2014-11-18 Impact factor: 3.168